Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.
OBJECTIVE
The inpatient dosing patterns and treatment costs in cancer and predialysis chronic kidney disease (CKD) patients treated with erythropoietic agents from a hospital pharmacy perspective were studied.


METHODS
An analysis of electronic inpatient records from the Premier Perspective comparative hospital database was conducted. Study participants were identified through hospitalizations recorded between July 2002 and March 2005 from over 500 hospitals nationwide. Adult patients with an admitting diagnosis of cancer or predialysis CKD and treated with epoetin alfa or darbepoetin alfa during hospitalization were included. Patients who had received renal dialysis or both agents during a hospitalization were excluded. Wholesale acquisition costs from September 2006 were used to calculate drug costs.


RESULTS
A total of 25,645 hospitalized patients with cancer (22,873 received epoetin alfa; 2,772 received darbepoetin alfa) and 66,822 hospitalized patients with CKD (60,079 received epoetin alfa; 6,743 received darbepoetin alfa) were identified. The mean cumulative dose per hospitalization resulted in dose ratios of 245:1 and 242:1 (units epoetin alfa:micrograms darbepoetin alfa) for cancer and CKD patients, respectively. On the basis of the cumulative dose per hospitalization, drug costs for darbepoetin alfa-treated patients were approximately 50% higher than drug costs for epoetin alfa-treated patients for both oncology and CKD patients.


CONCLUSIONS
Epoetin alfa was associated with less cost compared with darbepoetin alfa for treating inpatients with cancer or CKD. Further research including the patients' clinical outcomes is necessary to determine the true pharmacoeconomic differences between the two agents.
Vekeman
Francis
F
Analysis Group, Inc., Montreal, Quebec, Canada.
McKenzie
R Scott
RS
Lefebvre
Patrick
P
Watson
Sue H
SH
Mody
Samir H
SH
Piech
Catherine Tak
CT
Duh
Mei Sheng
MS
D000328:Adult; D000368:Aged; D000740:Anemia / Q000188:drug therapy*; D015331:Cohort Studies; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000191:economics; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007297:Inpatients; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D010607:Pharmacy Service, Hospital; D011994:Recombinant Proteins; D012189:Retrospective Studies